Aster Capital Management
CUE icon

Aster Capital Management’s Cue Biopharma CUE Stock Holding History

Aster Capital Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$54.6K Buy
+2,111
New +$62.6K 0.02% 561

Other funds holding CUE

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Texas Capital Bank Wealth Management Services
Texas Capital Bank Wealth Management Services Dallas, Texas $1.94B AUM 19.18% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Robertson Stephens Wealth Management
Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return

Aster Capital Management's CUE Position: Q3 2026 in Review

Aster Capital Management opened a new position in Cue Biopharma (CUE) in Q3 2026: 2,111 shares worth $54.6K. The stake represents 0.02% of the portfolio and ranks #561 among its holdings.

22 funds tracked by Wall St. Rank hold CUE as of Q3 2026.

  • Aster Capital Management held 2,111 shares of Cue Biopharma worth $54.6K as of Q3 2026.
  • Cue Biopharma was a new Aster Capital Management position in Q3 2026.
  • Cue Biopharma made up 0.02% of Aster Capital Management's portfolio in Q3 2026, its #561 holding.
  • 22 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.